Tenax Therapeutics, Inc. (TENX) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Tenax Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel formulations of levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) and imatinib for pulmonary arterial hypertension (PAH). The company is currently prioritizing its Phase 3 LEVEL trial for oral levosimendan and has suspended plans for an imatinib Phase 3 trial.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,960,469) | $(1,971,975) | $(11,334,982) | $(4,485,074) |
| Operating Expenses | $4,618,881 | $2,117,379 | $12,199,228 | $4,893,004 |
| Cash and Equivalents (End of Period) | $98,310,918 (as of Sept 30, 2024) | |||
| Working Capital | $97,221,938 (as of Sept 30, 2024) | |||
| Debt | $0 (Note payable fully repaid in Q3 2024) |
Material Changes vs. Prior Period
- Liquidity Transformation: Cash and cash equivalents increased from $9.8 million at December 31, 2023, to $98.3 million at September 30, 2024. This was driven by a private placement financing in August 2024 generating approximately $99.7 million in gross proceeds.
- Expense Growth: Total operating expenses for the nine months ended September 30, 2024, increased 149% to $12.2 million compared to $4.9 million in the prior year period. Research and Development (R&D) expenses surged 431% to $8.1 million, primarily due to the initiation and enrollment of the Phase 3 LEVEL trial.
- Debt Elimination: The company repaid its entire outstanding balance of a $500,903 premium finance note during the quarter ended September 30, 2024.
- Going Concern Status: Management determined that the substantial doubt regarding the company's ability to continue as a going concern has been alleviated due to the August 2024 financing, which is expected to fund operations through the end of 2027.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring substantial operating losses. Management believes current resources are sufficient to fund planned operations through the end of 2027.
- Clinical Strategy: The company is accelerating the Phase 3 LEVEL trial for oral levosimendan. With the new capital, they plan to initiate a second Phase 3 study in 2025. The imatinib Phase 3 trial has been suspended to prioritize levosimendan.
- Intellectual Property: The company holds U.S. patents covering IV and oral levosimendan for PH-HFpEF, with exclusivity extending through 2040 for the oral formulation.
- Risks: Risks include the uncertainty of clinical trial outcomes, the need for future capital if development timelines extend beyond 2027, and potential dilution from future equity issuances. The company has no revenue and relies entirely on financing.
Investor Verification Checklist
- Capital Runway: Verify the specific burn rate assumptions used to project operations through the end of 2027.
- Phase 3 Enrollment: Monitor the progress of patient enrollment in the LEVEL trial and the timeline for the planned second Phase 3 study.
- Dilution Impact: Review the terms of the August 2024 Offering, specifically the 31.9 million pre-funded warrants and 16.7 million warrants issued, and their potential impact on share count upon exercise.
- Licensing Obligations: Confirm the milestone payment structure with Orion Corporation, including the $10 million FDA approval milestone and potential commercial milestones up to $45 million.
- Stock Split Adjustments: Ensure all share counts and per-share metrics are reviewed in the context of the 1-for-80 reverse stock split effected in January 2024.